ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DYAI
ABOS (33) SCLX (40) PLUR (34) JSPR (36) ⌘ Pro Terminal →

Dyadic International Inc. (DYAI) — RQD Stock Rating Cockpit

$0.38 -1.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.38

Dyadic International Inc. (DYAI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $15.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DYAI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.38 (-1.10% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DYAI ranks #774 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DYAI compare to ABOS and SCLX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DYAI?
▼

Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.38 (-0.39%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (6)Whales (10)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.2% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE DYAI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYAI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY DYAI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$0.43-9.3% Next Q
Q2 (-2Q)
36
Grade E$0.39+0% Next Q
Q3 (-1Q)
34
Grade E$0.39-2.6% Next Q
Current
31
Grade E$0.38-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DYAI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DYAI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.40) forces dealer call-delta covering toward $1.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DYAI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DYAI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
40.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE3% OF RANGE
L: $0$0.38H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on DYAI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 24.9% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

13/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like DYAI
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYAI)

  • ✓Walkthrough of DYAI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DYAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.33%▲ RESISTANCE BREAKOUT
2026-11-03O $0.36H $0.38L $0.36C $0.38VOL 113.5K
RES: $0.37SUP: $0.20SMA50: $0.45SMA200: $0.76
$1.69$1.32$0.96$0.59$0.23RES $0.37SUP $0.20$0.382026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DYAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DYAI Butterfly Map → + Track DYAI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DYAI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DYAI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DYAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYAI)

Health Care Rank #774 of 1015 ⚔️ ABOS vs DYAI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DYAI vs. ABOS, SCLX, PLUR, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Dyadic International Inc. (DYAI) ranks #774 by composite RQD confidence (31/100, grade E) and #853 by equity capitalization ($15.2M). Within this direct 5-issuer industry benchmark cohort, DYAI leads on earnings valuation at N/A trailing P/E, while DYAI leads on capital efficiency and profitability with -35.0% ROIC and 24.9% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with DYAI at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DYAI ACTIVE
Dyadic International Inc.
E 31/100 — 24.9% -35.0% -1.10% $15.2M Benchmark Subject
ABOS
Acumen Pharmaceuticals Inc.
E 33/100 — — -35.0% +14.09% $15.2M /abos-vs-dyai →
SCLX
Scilex Holding Company
D- 40/100 — 96.0% -35.0% +1.08% $15.7M /sclx-vs-dyai →
PLUR
Pluri Inc.
E 34/100 — 49.0% -35.0% -3.23% $16.7M /plur-vs-dyai →
JSPR
Jasper Therapeutics Inc.
D- 36/100 — — -35.0% -2.35% $17.3M /jspr-vs-dyai →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213809 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyadic International Inc. (DYAI) reported GAAP revenue of $3.1M (-11.6% vs. FY2024 revenue of $3.5M , and +6.6% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$5.7M, and free cash flow of -$5.7M (-43.5% YoY). On the balance sheet, DYAI closed FY2025 with $9.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.1M -$7.4M -$5.7M -$5.7M $9.9M —
FY2024 (FY) 2024-12-31 $3.5M -$5.8M -$4.0M -$4.0M $9.9M —
FY2023 (FY) 2023-12-31 $2.9M -$6.8M -$6.7M -$6.7M — —

3. DYAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.38 (-1.10% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DYAI ranks #774 in composite RQD confidence.

How does DYAI compare to ABOS and SCLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DYAI?

Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DYAI trading relative to its 50-day, 200-day, and 52-week technical levels?

DYAI last traded at $0.38 (-1.10% on volume of 48,700 shares), positioning the stock -15.56% below its 50-day simple moving average ($0.45) and -50.00% below its 200-day simple moving average ($0.76). Across its 52-week range of $0.34 to $1.60, DYAI sits at the 3.2% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).

Direct Sub-Reports: DYAI RQD Cockpit DYAI 12M Forecast DYAI Earnings & Move DYAI Dividends & DRIP DYAI Insiders & 13F DYAI Whale Options DYAI Profit Sankey DYAI News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

DYAI — Dyadic International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Dyadic International Inc. (DYAI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.38 (-1.10% 1D, market capitalization $15.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 24.9%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Dyadic International Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the market data, gross margin is 24.9%, which indicates the company retains a portion of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Dyadic International Inc. (DYAI) reported $3.1M in annual revenue (up from $3.5M in FY2024, -11.6% YoY) and -$7.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.9M revenue, -$6.8M net income) through FY2025, DYAI scaled operating cash flow to -$5.7M and free cash flow to -$5.7M, backed by $9.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.34 – $1.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), DYAI carries a macro regime beta of 1.00 and gross margin of 24.9%.

  • Key Question #1: Can DYAI sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.1M and free cash flow of -$5.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is DYAI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DYAI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dyadic International Inc. (DYAI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DYAI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DYAI Bull vs. Bear Conversation Board — What's Your Call at $0.38?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DYAI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DYAI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $0.49 (+28.9%)
📌 Pinned Debate

Institutional whale 13F flow scores 10 of 20, the strongest RQD pillar, with a passive stake above 5% reported.

Picked up a starter position in DYAI in my $100K Virtual Cash book at $0.38. Institutional whale 13F flow scores 10 of 20, the strongest RQD pillar, with a passive stake above 5% reported.. Trading inside a $0.34–$1.60 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — DYAI's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.29 (-23.7%)
Spot @ $0.38

ROIC of -35% and FCF of -$5.7M against $4.6M cash, with a Piotroski F-Score of 2/9, signal forensic distress.

Careful chasing DYAI at $0.38. ROIC of -35% and FCF of -$5.7M against $4.6M cash, with a Piotroski F-Score of 2/9, signal forensic distress.. Gross margin is 24.9%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.29 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%